First US facility for Syngene

Indian CRDMO Syngene has agreed to acquire a biologics facility in Baltimore from Emergent BioSolutions, its first in the US, in a deal that should close within March. The overall investment is estimated around $50 million, including $36.5 million to buy it and expenses to make it operational. Emergent will retain the right to secure manufacturing capacity as needed.

The facility is fitted with multiple monoclonal antibody (mAb) lines and will bring Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services. The company added that this will bring cell line development, process optimisation and both clinical and commercial supply to customers in the pharma and animal health sectors when it becomes available for projects in 2H 2025.

“This comes in response to growing client demand in the US, the fastest-growing biologics market,” said Alex Del Priore, SVP of development and manufacturing services at Syngene International. “Most importantly, it increases the options we can offer our global customers, providing commercial-scale biologics manufacturing capabilities across our global network and will be underpinned by existing key client projects.”